Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public Citizen's FDA? Lurie Is Consumer Group's Third To Play Key Role At Agency

This article was originally published in The Pink Sheet Daily

Executive Summary

Public Citizen's Peter Lurie will be tasked with developing strategies to "facilitate" access to medical products that "meet critical public health needs."

You may also be interested in...



FDA Associate Commissioners Transition As PDUFA IV Rolls Over To V

Peter Lurie will replace David Dorsey as Acting Associate Commissioner for Policy and Planning, and Melinda Plaisier becomes Acting Associate Commissioner for Regulatory Affairs as Dara Corrigan moves to FDA’s European office.

Lilly Outside "Faculty" Is Headed By 22 Physicians Receiving $50,000 Or More

The most highly paid Lilly outside physician consultant in the first quarter of 2009 - San Jose, Calif., psychiatrist Manoj Waikar ($70,050) - says he was convinced that the public listing of financial ties was a good idea when his patients said they approved of his work with pharmaceutical companies

Public Citizen Seeks To Hold Up Lilly Prasugrel Review For Further Data

Public Citizen's decision to file a citizen petition June 3 asking FDA to halt its review of Lilly/Daiichi Sankyo's prasugrel suggests the watchdog group may believe the agency is on the verge of approving the platelet inhibitor

Related Content

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel